📊 LFWD Key Takeaways
Is Lifeward Ltd. (LFWD) a Good Investment?
Despite exceptional 1473.9% YoY revenue growth, Lifeward is in severe financial distress with unsustainable cash burn of $16.8M annually against only $2.2M in cash reserves, creating an imminent solvency crisis. Operating expenses of ~$28M far exceed the $8.4M gross profit, indicating fundamental business model dysfunction where revenue growth is not translating to viable unit economics or profitability.
Despite hypergrowth in revenue, Lifeward is deeply unprofitable with operating and net margins near -90% and a -$16.8M operating cash burn. With just $2.2M in cash, a sub-1 quick ratio, and limited debt capacity, near-term financing and dilution risk are high. Fundamentals need clear gross margin expansion and operating leverage before this becomes investable on fundamentals.
Why Buy Lifeward Ltd. Stock? LFWD Key Strengths
- Exceptional revenue growth of 1473.9% YoY indicates strong market demand for orthopedic/prosthetic products
- Reasonable gross margin of 38.2% suggests acceptable pricing power in the medical device sector
- Low long-term debt of $394K provides minimal leverage burden
- Explosive top-line growth (+1473.9% YoY)
- Very low leverage with negligible long-term debt
- Asset-light with minimal capex and 38% gross margin
LFWD Stock Risks: Lifeward Ltd. Investment Risks
- Critical liquidity crisis: $16.8M annual operating cash burn with only $2.2M cash reserves equals <2 months runway before insolvency
- Operating margin of -89.3% and deteriorating net losses despite revenue growth indicate fundamental cost structure misalignment with revenue base
- Quick ratio of 0.84 signals immediate working capital stress; company will require external funding or face bankruptcy within months
- Operating expenses (~$28M) massively exceed gross profit ($8.4M), suggesting company loses money on operations despite revenue
- No clear path to profitability evident in trajectory; revenue growth obscures deteriorating underlying economics
- Acute liquidity risk given cash vs. burn
- Sustained negative FCF and -90% operating/net margins
- High probability of dilution or going-concern pressure
Key Metrics to Watch
- Quarterly cash burn rate and cash position - any quarterly decline below $1M remaining cash triggers terminal risk
- Operating expense ratio relative to revenue - must decline significantly or profitability is impossible
- Funding announcements or debt issuance - necessity indicates capital crisis validation
- Quarterly free cash flow (FCF)
- Gross and operating margin trajectory
Lifeward Ltd. (LFWD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Lifeward Ltd. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
LFWD Profit Margin, ROE & Profitability Analysis
LFWD vs Healthcare Sector: How Lifeward Ltd. Compares
How Lifeward Ltd. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Lifeward Ltd. Stock Overvalued? LFWD Valuation Analysis 2026
Based on fundamental analysis, Lifeward Ltd. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Lifeward Ltd. Balance Sheet: LFWD Debt, Cash & Liquidity
LFWD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Lifeward Ltd.'s revenue has grown significantly by 224% over the 5-year period, indicating strong business expansion. The most recent EPS of $-31.13 indicates the company is currently unprofitable.
LFWD Revenue Growth, EPS Growth & YoY Performance
LFWD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.2M | -$3.1M | $-0.20 |
| Q2 2025 | $900.0K | -$4.3M | $-0.50 |
| Q1 2025 | $500.0K | -$4.8M | $-0.46 |
| Q3 2024 | $1.6M | -$3.1M | $-0.35 |
| Q2 2024 | $988.0K | -$4.3M | $-0.50 |
| Q1 2024 | $489.0K | -$4.3M | $-0.51 |
| Q3 2023 | $290.0K | -$5.5M | $-0.09 |
| Q2 2023 | $205.0K | -$4.4M | $-0.07 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Lifeward Ltd. Dividends, Buybacks & Capital Allocation
LFWD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Lifeward Ltd. (CIK: 0001607962)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LFWD
What is the AI rating for LFWD?
Lifeward Ltd. (LFWD) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 88% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are LFWD's key strengths?
Claude: Exceptional revenue growth of 1473.9% YoY indicates strong market demand for orthopedic/prosthetic products. Reasonable gross margin of 38.2% suggests acceptable pricing power in the medical device sector. ChatGPT: Explosive top-line growth (+1473.9% YoY). Very low leverage with negligible long-term debt.
What are the risks of investing in LFWD?
Claude: Critical liquidity crisis: $16.8M annual operating cash burn with only $2.2M cash reserves equals <2 months runway before insolvency. Operating margin of -89.3% and deteriorating net losses despite revenue growth indicate fundamental cost structure misalignment with revenue base. ChatGPT: Acute liquidity risk given cash vs. burn. Sustained negative FCF and -90% operating/net margins.
What is LFWD's revenue and growth?
Lifeward Ltd. reported revenue of $22.0M.
Does LFWD pay dividends?
Lifeward Ltd. does not currently pay dividends.
Where can I find LFWD SEC filings?
Official SEC filings for Lifeward Ltd. (CIK: 0001607962) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LFWD's EPS?
Lifeward Ltd. has a diluted EPS of $-17.16.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LFWD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Lifeward Ltd. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is LFWD stock overvalued or undervalued?
Valuation metrics for LFWD: ROE of -236.8% (sector avg: 15%), net margin of -90.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LFWD stock in 2026?
Our dual AI analysis gives Lifeward Ltd. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is LFWD's free cash flow?
Lifeward Ltd.'s operating cash flow is $-16.8M, with capital expenditures of $16.0K. FCF margin is -76.4%.
How does LFWD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -90.4% (avg: 12%), ROE -236.8% (avg: 15%), current ratio 1.31 (avg: 2).